SYK · NYSE · Health Care Equipment
Health Care Equipment company based in Kalamazoo, Michigan.
Last close, Oct 1, 2026
$272.96
Adjusted for splits and dividends
Last 12 months
-25.0%
S&P 500 +14.3% over the same dates
Market value
$105B
Last close × shares outstanding
Bets against the stock: 7.67M shares sold short (2.0% of shares outstanding), +0.4% vs the previous count, 2.2 days of normal trading to buy them back. FINRA, as of Sep 15, 2026.
Insiders buying, last 90 days
1 insider
$27K bought in total
Insiders selling, last 90 days
22 sales
$118M sold. Insiders sell for many reasons.
New federal contracts, 12 months
None
Nothing found for this company
Revenue, fiscal 2025
$25.1B
+11.2% vs the year before
Net income, fiscal 2025
$3.25B
As reported in the annual filing
Shares outstanding
384M
As of Jun 30, 2026
In fiscal 2025 the company spent $1.28B on dividends. Cash actually paid, from its cash-flow statement.
Traded 22 days after results
113 → 131 shares held+16% of their stake
A board member of Stryker Corporation spent $4.1K of their very own money to buy Stryker Corporation shares. It was the first time in 29 months that they bought. Their pile of Stryker Corporation shares grew by 16%.
Traded 12 days after results
63 → 99 shares held+57% of their stake
A board member of Stryker Corporation spent $7K of their very own money to buy Stryker Corporation shares. It was the first time in 8 months that they bought. Their pile of Stryker Corporation shares grew by 57%.
Traded 43 days after results
99 → 102 shares held+3% of their stake
A board member of Stryker Corporation spent $557 of their very own money to buy Stryker Corporation shares.
Traded 64 days after results
0 → 63 shares held
A board member of Stryker Corporation spent $13K of their very own money to buy Stryker Corporation shares.
Traded 49 days after results
-11 → 0 shares held
A board member of Stryker Corporation spent $2.4K of their very own money to buy Stryker Corporation shares.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Short sale volume: 43.4% of the volume reported to FINRA over the last 20 trading days was marked short, below its 1-year average of 50.3%. FINRA daily files, to Oct 2, 2026.
Fails to deliver: 180K shares (about $54.4M) were not delivered on time for settlement on Sep 8, 2026. SEC fails-to-deliver data.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock. Fails to deliver have many causes, including processing delays, and are often resolved within days.
26 certified in FY2026 Q3, vs 43 a year earlier. 26 positions in total, median offered wage $122K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Last 12 months, adjusted daily closes
Adjusted close went from $364.15 on Oct 1, 2025 to $272.96 on Oct 1, 2026 (-25.0%). Disclosed trades in the last 12 months: 0 insider purchases, 71 insider sales (6 under pre-arranged plans), 3 Congress purchases, 6 Congress sales.
35 approvals or clearances and 72 recalls recorded by the FDA for this company and its listed subsidiaries.
From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.
